A new protoapigenone analog RY10-4 induces apoptosis and suppresses invasion through the PI3K/Akt pathway in human breast cancer

Cancer Letters

Volumn 324, Issue 2, 2012, Pages 210-220

  Yuan, Qianying ^a   Cai, Shaoxin ^a   Zhang, Xuenong ^a   Liu, Ziwei ^a   Li, Zhaoming ^a   Luo, Xuelai ^a   Xiong, Chaomei ^a   Wang, Jianping ^a   Hu, Junbo ^a   Ruan, Jinlan ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Anti tumor; Breast cancer; PI3K Akt; RY10 4

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; METHYLENE BLUE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RY 10 4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER INVASION; CELL CYCLE ARREST; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; S PHASE CELL CYCLE CHECKPOINT; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTO-ONCOGENE PROTEINS C-AKT; PYRONES; S PHASE CELL CYCLE CHECKPOINTS; SIGNAL TRANSDUCTION; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84864382501     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.05.025     Document Type: Article

References (46)

1. Testa J.R., Bellacosa A. AKT plays a central role in tumorigenesis. Proc. Natl. Acad. Sci. USA 2001, 98:10983-10985.
2. Nicholson K.M., Anderson N.G. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002, 14:381-395.
3. Liu P., Cheng H., Roberts T.M., Zhao J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 2009, 8:627-644.
4. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 2002, 296:1655-1657.
5. Lee J.W., Soung Y.H., Kim S.Y., Lee H.W., Park W.S., Nam S.W., Kim S.H., Lee J.Y., Yoo N.J., Lee S.H. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005, 24:1477-1480.
6. De Laurentiis A., Pardo O.E., Palamidessi A., Jackson S.P., Schoenwaelder S.M., Reichmann E., Scita G., Arcaro A. The catalytic class I(A) PI3K isoforms play divergent roles in breast cancer cell migration. Cell Signal 2011, 23:529-541.
7. Duronio V., Scheid M.P., Ettinger S. Downstream signalling events regulated by phosphatidylinositol 3-kinase activity. Cell Signal 1998, 10:233-239.
8. Jiang B.H., Zheng J.Z., Aoki M., Vogt P.K. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc. Natl. Acad. Sci. USA 2000, 97:1749-1753.
9. Engelman J.A., Luo J., Cantley L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 2006, 7:606-619.
10. Kim D., Kim S., Koh H., Yoon S.O., Chung A.S., Cho K.S., Chung J. Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. Faseb J. 2001, 15:1953-1962.
11. Bellacosa A., de Feo D., Godwin A.K., Bell D.W., Cheng J.Q., Altomare D.A., Wan M., Dubeau L., Scambia G., Masciullo V., Ferrandina G., Benedetti Panici P., Mancuso S., Neri G., Testa J.R. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer 1995, 64:280-285.
12. Staal S.P. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc. Natl. Acad. Sci. USA 1987, 84:5034-5037.
13. Yamamoto S., Tomita Y., Hoshida Y., Morooka T., Nagano H., Dono K., Umeshita K., Sakon M., Ishikawa O., Ohigashi H., Nakamori S., Monden M., Aozasa K. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin. Cancer Res. 2004, 10:2846-2850.
14. Vazquez F., Sellers W.R. The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling. Biochim. Biophys. Acta. 2000, 1470:M21-35.
15. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C., Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947.
16. Khan S., Kumagai T., Vora J., Bose N., Sehgal I., Koeffler P.H., Bose S. PTEN promoter is methylated in a proportion of invasive breast cancers. Int. J. Cancer 2004, 112:407-410.
17. Steck P.A., Pershouse M.A., Jasser S.A., Yung W.K., Lin H., Ligon A.H., Langford L.A., Baumgard M.L., Hattier T., Davis T., Frye C., Hu R., Swedlund B., Teng D.H., Tavtigian S.V. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 1997, 15:356-362.
18. Suzuki H., Freije D., Nusskern D.R., Okami K., Cairns P., Sidransky D., Isaacs W.B., Bova G.S. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res. 1998, 58:204-209.
19. Li G., Robinson G.W., Lesche R., Martinez-Diaz H., Jiang Z., Rozengurt N., Wagner K.U., Wu D.C., Lane T.F., Liu X., Hennighausen L., Wu H. Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development 2002, 129:4159-4170.
20. Backman S.A., Ghazarian D., So K., Sanchez O., Wagner K.U., Hennighausen L., Suzuki A., Tsao M.S., Chapman W.B., Stambolic V., Mak T.W. Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten. Proc. Natl. Acad. Sci. USA 2004, 101:1725-1730.
21. Lin A.S., Chang F.R., Wu C.C., Liaw C.C., Wu Y.C. New cytotoxic flavonoids from Thelypteris torresiana. Planta Med. 2005, 71:867-870.
22. Huang X.H., Xiong P.C., Xiong C.M., Cai Y.L., Wei A.H., Wang J.P., Liang X.F., Ruan J.L. In vitro and in vivo antitumor activity of Macrothelypteris torresiana and its acute/subacute oral toxicity. Phytomedicine 2010, 17:930-934.
23. Yuan Q., Liu Z., Xiong C., Wu L., Wang J., Ruan J. A novel, broad-spectrum antitumor compound containing the 1-hydroxycyclohexa-2,5-dien-4-one group: The disclosure of a new antitumor pharmacophore in protoapigenone 1. Bioorg. Med. Chem. Lett. 2011, 21:3427-3430.
24. Yeo E.J., Chun Y.S., Cho Y.S., Kim J., Lee J.C., Kim M.S., Park J.W. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J. Natl. Cancer Inst. 2003, 95:516-525.
25. Brognard J., Clark A.S., Ni Y., Dennis P.A. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 2001, 61:3986-3997.
26. Martelli A.M., Tazzari P.L., Tabellini G., Bortul R., Billi A.M., Manzoli L., Ruggeri A., Conte R., Cocco L. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells. Leukemia 2003, 17:1794-1805.
27. Clark A.S., West K., Streicher S., Dennis P.A. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol. Cancer Ther. 2002, 1:707-717.
28. Chiu C.C., Chang H.W., Chuang D.W., Chang F.R., Chang Y.C., Cheng Y.S., Tsai M.T., Chen W.Y., Lee S.S., Wang C.K., Chen J.Y., Wang H.M., Chen C.C., Liu Y.C., Wu Y.C. Fern plant-derived protoapigenone leads to DNA damage, apoptosis, and G(2)/m arrest in lung cancer cell line H1299. DNA Cell Biol. 2009, 28:501-506.
29. Liu H., Xiao Y., Xiong C., Wei A., Ruan J. Apoptosis induced by a new flavonoid in human hepatoma HepG2 cells involves reactive oxygen species-mediated mitochondrial dysfunction and MAPK activation. Eur. J. Pharmacol. 2011, 654:209-216.
30. Lin A.S., Nakagawa-Goto K., Chang F.R., Yu D., Morris-Natschke S.L., Wu C.C., Chen S.L., Wu Y.C., Lee K.H. First total synthesis of protoapigenone and its analogues as potent cytotoxic agents. J. Med. Chem. 2007, 50:3921-3927.
31. Chang H.L., Su J.H., Yeh Y.T., Lee Y.C., Chen H.M., Wu Y.C., Yuan S.S. Protoapigenone, a novel flavonoid, inhibits ovarian cancer cell growth in vitro and in vivo. Cancer Lett. 2008, 267:85-95.
32. H.M. Chen, F.R. Chang, Y.C. Hsieh, Y.J. Cheng, K.C. Hsieh, L.M. Tsai, A.S. Lin, Y.C. Wu, S.S. Yuan A novel synthetic protoapigenone analogue, WYC02-9, induces DNA damage and apoptosis in DU145 prostate cancer cells through generation of reactive oxygen species. Free Radic. Biol. Med. 50, 1151-1162.
33. Dan S., Yoshimi H., Okamura M., Mukai Y., Yamori T. Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0/G1 arrest. Biochem. Biophys. Res. Commun. 2009, 379:104-109.
34. Jiang B.H., Liu L.Z. PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim. Biophys. Acta 2008, 1784:150-158.
35. Jakubikova J., Sedlak J., Mithen R., Bao Y. Role of PI3K/Akt and MEK/ERK signaling pathways in sulforaphane- and erucin-induced phase II enzymes and MRP2 transcription, G2/M arrest and cell death in Caco-2 cells. Biochem. Pharmacol. 2005, 69:1543-1552.
36. Moon D.O., Kim M.O., Choi Y.H., Kim G.Y. Beta-Sitosterol induces G2/M arrest, endoreduplication, and apoptosis through the Bcl-2 and PI3K/Akt signaling pathways. Cancer Lett. 2008, 264:181-191.
37. Wang J., Wu A., Xu Y., Liu J., Qian X. M(2)-A induces apoptosis and G(2)-M arrest via inhibiting PI3K/Akt pathway in HL60 cells. Cancer Lett. 2009, 283:193-202.
38. Meng Q., Xia C., Fang J., Rojanasakul Y., Jiang B.H. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell Signal 2006, 18:2262-2271.
39. Liu H., Xiao Y., Xiong C., Wei A., Ruan J. Apoptosis induced by a new flavonoid in human hepatoma HepG2 cells involves reactive oxygen species-mediated mitochondrial dysfunction and MAPK activation. Eur. J. Pharmacol. 2011, 654:209-216.
40. Nicholson D.W., Thornberry N.A. Caspases: killer proteases. Trends Biochem. Sci. 1997, 22:299-306.
41. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2:489-501.
42. Krystal G.W., Sulanke G., Litz J. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol. Cancer. Ther. 2002, 1:913-922.
43. Sousa L.P., Carmo A.F., Rezende B.M., Lopes F., Silva D.M., Alessandri A.L., Bonjardim C.A., Rossi A.G., Teixeira M.M., Pinho V. Cyclic AMP enhances resolution of allergic pleurisy by promoting inflammatory cell apoptosis via inhibition of PI3K/Akt and NF-kappaB. Biochem. Pharmacol. 2009, 78:396-405.
44. Fresno Vara J.A., Casado E., de Castro J., Cejas P., Belda-Iniesta C., Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 2004, 30:193-204.
45. Chen B., Su B., Chen S. A COX-2 inhibitor nimesulide analog selectively induces apoptosis in Her2 overexpressing breast cancer cells via cytochrome c dependent mechanisms. Biochem. Pharmacol. 2009, 77:1787-1794.
46. Huang C.Y., Fong Y.C., Lee C.Y., Chen M.Y., Tsai H.C., Hsu H.C., Tang C.H. CCL5 increases lung cancer migration via PI3K, Akt and NF-kappaB pathways. Biochem. Pharmacol. 2009, 77:794-803.